Cognition Therapeutics Inc (CGTX) FinancialsCGTXCognition Therapeutics Inc

Evaluating the bottom line, Cognition Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -83.76%, provide a clear picture of how effectively CGTX converts its operational activities into shareholder value.

In the context of the broader market, CGTX competes directly with industry leaders such as MBOT and ICCC. With a market capitalization of $96.04M, it holds a significant position in the sector. When comparing efficiency, CGTX's gross margin of N/A stands against MBOT's -266.80% and ICCC's 33.92%. Such benchmarking helps identify whether Cognition Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Cognition Therapeutics has shown a consistent reduction in net losses, with the latest reported loss of $3.9 million for Q2 2026, compared to $6.7 million a year earlier. The company also maintains a strong cash position of approximately $34.8 million, which is projected to fund operations into Q4 2027, supporting ongoing R&D efforts.